Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.806 EUR | -0.66% | -5.45% | -50.25% |
04-04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
04-03 | AB Science: reconsideration possible for masitinib in ALS | CF |
Evolution of the average Target Price on AB Science
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
EPS Revisions
Annual profits - Rate of surprise
- Stock Market
- Equities
- AB Stock
- A8D Stock
- Consensus AB Science